{
  "source": "PA-Notification-Crenessity.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1471-1\nProgram Prior Authorization/Notification\nMedication Crenessity™(crinecerfont) oral capsule and oral suspension\nP&T Approval Date 2/2025\nEffective Date 4/1/2025\n1. Background:\nCrenessity (crinecerfont) is a corticotropin-releasing factor type 1 receptor antagonist indicated\nas adjunctive treatment to glucocorticoid replacement to control androgens in adults and\npediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Crenessity will be approved based upon all of the following criteria:\na. Diagnosis of classic congenital adrenal hyperplasia (CAH)\n-AND-\nb. Patient is 4 years of age or older\n-AND-\nc. Patient will receive concomitant glucocorticoid replacement (e.g., dexamethasone,\nhydrocortisone, methylprednisolone, prednisone, prednisolone)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Crenessity will be approved based upon both of the following criteria:\na. Documentation of positive clinical response to Crenessity therapy\n-AND-\nb. Patient will continue to receive concomitant glucocorticoid replacement (e.g.,\ndexamethasone, hydrocortisone, methylprednisolone, prednisone, prednisolone)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. Reference:\n1. Crenessity [package insert]. San Diego, CA: Neuroc",
    "ic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. Reference:\n1. Crenessity [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.; December 2024.\nProgram Prior Authorization/Notification - Crenessity (crinecerfont)\nChange Control\n2/2025 New program\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}